TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2020

A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera

Jeff P Sharman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.